Literature DB >> 17101642

Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice.

Sarah S Bubeck1, Angelene M Cantwell, Peter H Dube.   

Abstract

Yersinia pestis is the causative agent of plague, a disease that can manifest as either bubonic or pneumonic plague. An interesting feature of plague is that it is a rapidly progressive disease, suggesting that Y. pestis either evades and/or suppresses the innate immune response to infection. Therefore, the early host response during the course of primary pneumonic plague was investigated in two mouse strains, the outbred strain CD1 and the inbred strain C57BL/6. A comparative analysis of the course of disease in these two strains of mice indicated that they are susceptible to intranasal Y. pestis CO92 infection and have similar 50% lethal doses and kinetics of infection with respect to colonization of the lung, liver, and spleen. Significantly, in both strains of mice, robust neutrophil recruitment to the lungs was not observed until 48 h after infection, suggesting that there was a delay in inflammatory cell recruitment to the site of infection. In addition, proinflammatory cytokines (interleukin-6 [IL-6], tumor necrosis factor alpha, gamma interferon, IL-12p70, monocyte chemoattractant protein 1) and chemokines (KC, MIP-2) in the bronchoalveolar lavage fluids were not readily detected until 48 h after infection, which coincided with the increase in polymorphonuclear leukocyte (PMN) recruitment to the lungs. In comparison, CD1 mice with gram-negative pneumonia caused by Klebsiella pneumoniae exhibited strong inflammatory responses early in infection, with PMNs comprising the majority of the cells in the bronchoalveolar lavage fluid 24 h postinfection, indicating that PMN recruitment to the lungs could occur earlier in this infection than in Y. pestis infection. Together, our results indicate that there is a delay in the recruitment of neutrophils to the lungs in the mouse model of primary plague pneumonia that correlates with delayed expression of proinflammatory cytokines and chemokines in both outbred and inbred mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101642      PMCID: PMC1828510          DOI: 10.1128/IAI.00403-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Pneumonic plague in mice; the effect of polyvinylpyrrolidone.

Authors:  P N SMITH
Journal:  Am J Hyg       Date:  1959-01

2.  Pneumonic plague in mice: modification of the infection by antibody against specific components of Pasteurella pestis.

Authors:  P N SMITH
Journal:  J Infect Dis       Date:  1959 Jan-Feb       Impact factor: 5.226

3.  Ambiguous role of interleukin-12 in Yersinia enterocolitica infection in susceptible and resistant mouse strains.

Authors:  E Bohn; E Schmitt; C Bielfeldt; A Noll; R Schulte; I B Autenrieth
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  Functional characterization of the rat chemokine KC and its importance in neutrophil recruitment in a rat model of pulmonary inflammation.

Authors:  C W Frevert; S Huang; H Danaee; J D Paulauskis; L Kobzik
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

5.  Comparison of the immune response to three different Yersinia pestis vaccines in guinea pigs and langurs.

Authors:  T H Chen; L E Foster; K F Meyer
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Kinetics of disease progression and host response in a rat model of bubonic plague.

Authors:  Florent Sebbane; Donald Gardner; Daniel Long; Brian B Gowen; B Joseph Hinnebusch
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

7.  Characterization of oral Yersinia enterocolitica infection in three different strains of inbred mice.

Authors:  Scott A Handley; Peter H Dube; Paula A Revell; Virginia L Miller
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

8.  A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice.

Authors:  Margaret Morton; Helen S Garmory; Stuart D Perkins; Aisling M O'Dowd; Kate F Griffin; Arthur K Turner; Alice M Bennett; Richard W Titball
Journal:  Vaccine       Date:  2004-06-30       Impact factor: 3.641

9.  Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.

Authors:  R Nakajima; R R Brubaker
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

10.  Protective role of interleukin-6 during Yersinia enterocolitica infection is mediated through the modulation of inflammatory cytokines.

Authors:  Peter H Dube; Scott A Handley; James Lewis; Virginia L Miller
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

View more
  56 in total

1.  Pulmonary infection by Yersinia pestis rapidly establishes a permissive environment for microbial proliferation.

Authors:  Paul A Price; Jianping Jin; William E Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-01       Impact factor: 11.205

2.  Primary pneumonic plague in the African Green monkey as a model for treatment efficacy evaluation.

Authors:  R Colby Layton; Trevor Brasel; Andrew Gigliotti; Edward Barr; Steven Storch; Leslie Myers; Charles Hobbs; Frederick Koster
Journal:  J Med Primatol       Date:  2010-08-16       Impact factor: 0.667

3.  Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation.

Authors:  Jorge L Medina; Jacqueline J Coalson; Edward G Brooks; Vicki T Winter; Adriana Chaparro; Molly F R Principe; Thirumalai R Kannan; Joel B Baseman; Peter H Dube
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

4.  Transcriptomic and innate immune responses to Yersinia pestis in the lymph node during bubonic plague.

Authors:  Jason E Comer; Daniel E Sturdevant; Aaron B Carmody; Kimmo Virtaneva; Donald Gardner; Dan Long; Rebecca Rosenke; Stephen F Porcella; B Joseph Hinnebusch
Journal:  Infect Immun       Date:  2010-09-27       Impact factor: 3.441

5.  Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague.

Authors:  Stephen T Smiley; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Jr-Shiuan Lin
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

6.  Redundant and Cooperative Roles for Yersinia pestis Yop Effectors in the Inhibition of Human Neutrophil Exocytic Responses Revealed by Gain-of-Function Approach.

Authors:  Amanda R Pulsifer; Aruna Vashishta; Shane A Reeves; Jennifer K Wolfe; Samantha G Palace; Megan K Proulx; Jon Goguen; Sobha R Bodduluri; Bodduluri Haribabu; Silvia M Uriarte; Matthew B Lawrenz
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

7.  Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Authors:  Richard J Thomas; Daniel Webber; Aaron Collinge; Anthony J Stagg; Stephen C Bailey; Alejandro Nunez; Amanda Gates; Pramukh N Jayasekera; Rosa R Taylor; Steve Eley; Richard W Titball
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

8.  YopH inhibits early pro-inflammatory cytokine responses during plague pneumonia.

Authors:  Angelene M Cantwell; Sarah S Bubeck; Peter H Dube
Journal:  BMC Immunol       Date:  2010-06-16       Impact factor: 3.615

9.  Activation of innate immune antiviral responses by Nod2.

Authors:  Ahmed Sabbah; Te Hung Chang; Rosalinda Harnack; Victoria Frohlich; Kaoru Tominaga; Peter H Dube; Yan Xiang; Santanu Bose
Journal:  Nat Immunol       Date:  2009-08-23       Impact factor: 25.606

10.  Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin.

Authors:  R Doug Hardy; Jacqueline J Coalson; Jay Peters; Adriana Chaparro; Chonnamet Techasaensiri; Angelene M Cantwell; T R Kannan; Joel B Baseman; Peter H Dube
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.